Imugene Ltd · ASX:IMU
Imugene — Investor Presentation (July 2026)
29 slides from Imugene's investor presentation, Jul 7, 2026
Slide 1: Innovation in Cancer Treatment: Capital Raising Presentation
ASX:IMU For personal use only Innovation in Cancer Treatment Capital Raising Presentation July 2026 Release authorised by the Managing Director and Chief Executive Officer Imugene Limited 1
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Imugene Limited (ASX: IMU) (Company) in connection with a two tranche non- International offer restrictions - This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United underwritt
Slide 3: Imugene is a clinical stage cancer company developing an allogeneic CAR-T
For personal use only Imugene is a clinical stage cancer company developing an allogeneic CAR-T for blood cancer 3
Slide 4: Executive Summary
Executive Summary Azer-cel is an off-the-shelf CAR T therapy with compelling efficacy, regulatory clarity, and multiple capital-efficient paths to market Overview & Market Opportunity Clinical Validation Upcoming Catalysts For personal use only Lead program azer-cel: off-the-shelf (allogeneic) Desig
Slide 5: Azer-cel: Development Timeline
Azer-cel: Development Timeline Key milestones achieved since March 2026 capital raising and approaching Pharma collaboration window PHARMA COLLABORATION WINDOW For personal use only ACHIEVED MILESTONES UPCOMING MILESTONES Jun 2026 Concurrent BTKi Complete 82% ORR 83% ORR Cohort FPI + Response Phase
Slide 6: Experienced Leadership Team and BoD has brought FDA-Approved Drugs to Market
Experienced Leadership Team and BoD has brought FDA-Approved Drugs to Market Executive Management Team For personal use only Leslie Chong John Byon, MD, PhD Ursula McCurry Darren Keamy Chief Executive Officer Chief Medical Chief Clinical Chief Financial Officer & & Managing Director Officer Operatio
Slide 7: Azer-cel Overview
For personal use only Azer-cel Overview 7 7
Slide 8: How is Imugene different? Allogeneic vs Autologous CAR-T
How is Imugene different? Allogeneic vs Autologous CAR-T Allogeneic CAR-T Cell Therapy is significantly differentiated from approved Autologous CAR-T therapies on cost and wait times Autologous Allogeneic Autologous Allogeneic For personal use only Overview • Autologous CAR-T cells • Dose for multip
Slide 9: Introducing azer-cel
Introducing azer-cel Imugene’s potential first-in-class, off-the-shelf Allogeneic CAR-T Cell Therapy 1 For personal use only “Off-the-shelf” CD19 Allogeneic CAR-T 1. Collection from healthy donor 2 Addresses high and growing unmet need in blood cancers 2. Genetic Modification 3 Current Phase 1b stud
Slide 10: Azer-cel Phase 1b Study
Azer-cel Phase 1b Study Dose expansion is currently enrolling across CAR-T relapsed, CAR-T naïve and concurrent BTKi combination cohorts Cohort 1 CAR-T Relapsed DLBCL For personal use only • First patient dosed in April, 2024 (n=22) Positive FDA Type C meeting in • 82% ORR (14/17) in 3L+ DLBCL, incl
Slide 11: Azer-cel Commercialization Opportunity
Azer-cel Commercialization Opportunity $3bn+ p.a. US potential market opportunity in rare & niche indications and 3L+ DLBCL AZER CEL US INCIDENCE 1 ELIGIBLE FOR CAR-T 2 MARKET OPPORTUNITY 3 MZL For personal use only WM 4500 MZL MZL 1000 1200 $480M PCNSL 1500 DLBCL/HGBCL DLBCL/HGBCL WM DLBCL/HGBCL WM
Slide 12: Azer-cel Phase 1b Study
For personal use only Azer-cel Phase 1b Study 12 12
Slide 13: Compelling Cohort Phase 1b data in DLBCL to date
Compelling Cohort 1 Phase 1b data in DLBCL to date 82% Overall Response Rate in Relapsed/Refractory (R/R) DLBCL Cohort 1 of the Phase 1b study evaluates azer-cel in heavily pre-treated 3L+ patients with R/R DLBCL, including patients who have failed prior autologous CAR-T therapy For personal use onl
Slide 14: Azer-cel compared to existing Approved Auto CAR-T Therapies
Azer-cel compared to existing Approved Auto CAR-T Therapies Initial azer-cel Ph 1b R/R DLBCL data is compelling when compared to approved Auto CAR-T treatments For personal use only Azer-cel is comparable to approved Auto CAR-Ts for treatment of DLBCL 2L+ of therapy1 82% 74% 73% Overall 52% Despite
Slide 15: Azer-cel Clinical Development
For personal use only Azer-cel Clinical Development 15 15
Slide 16: Azer-cel Phase 1/1b Study Design
Azer-cel Phase 1/1b Study Design Dose Escalation Dose Expansion Cohorts For personal use only N=84 (Complete) N=50+ (Currently enrolling) The Recommended Phase 2 1. CAR-T 2. CAR-T 3. Concurrent Regimen was determined to be: Relapsed Naive BTKi • 500M cells • Aug/Cy – Flu 30mg/m2 x 3 days, Cy 750mg/m
Slide 17: Cohort 2: CAR-T naïve patients show strong overall response rate
Cohort 2: CAR-T naïve patients show strong overall response rate in multiple indications Cohort 2 evaluates azer-cel in CAR-T naïve patients across rare and niche lymphomas RESULTS & KEY TAKEAWAYS For personal use only 2026 American Society of Clinical Oncology (ASCO) Objective Response Rate (CR + P
Slide 18: Cohort 2: CAR-T Naïve Subset Indication
18 Cohort 2: CAR-T Naïve Subset Indication On-going Responses In MZL & CLL/SLL • In CLL/SLL, CRs are uncommon MZL CLL and ORR (including PRs) has For personal use only supported regulatory approvals 1062-022 4026-001 (U.S. FDA guidance). 1001-003 • To be eligible for study, all CLL 4002-005 4002-007
Slide 19: Cohort 3: BTKi Market is Large and Growing
Cohort 3: BTKi Market is Large and Growing Combination with existing BTKi’s to increase registrational and commercial opportunity For personal use only • BTK inhibitors are an established standard of care across multiple B-cell malignancies with >US$10bn in annual global sales Annual Revenue BTKi Dr
Slide 20: Cohort 3: BTKi + azer-cel Concurrent Combination
Cohort 3: BTKi + azer-cel Concurrent Combination Combination Supports Expanded Registrational and Commercial Opportunity First Two Evaluable Patients Achieved a Complete Response (CR) July 2026 For personal use only BTK inhibitors are an established standard of care across multiple B-cell malignanci
Slide 21: Proposed Clinical Pathway: Registrational Strategy
Proposed Clinical Pathway: Azer-cel Allogeneic CD19 CAR-T 2026 Provides Opportunity to Progress Toward 2026 Execution Registrational Strategy For personal use only Clinical Manufacturing & Supply Continue advancement of azer-cel across Cohorts 2 and 3: • Continued enrollment and • Scale-up and valid
Slide 22: Capital Raising Overview
For personal use only Capital Raising Overview 2222
Slide 23: Capital Raising Summary
Capital Raising Summary Two-tranche Placement of ~A$11.1 million to advance azer-cel through critical clinical, regulatory and manufacturing milestones • Imugene has raised approximately A$11.1 million (before costs) via the issue of approximately 117.1 million fully paid ordinary shares in the Comp
Slide 24: Sources & Uses
Sources & Uses Raising proceeds to be used to continue the ongoing development of azer-cel through the expansion of Cohort 2 and the new Cohort 3 (BTKi) of its Phase 1b trial, funding the Company into CY2027 For personal use only • Offer proceeds of ~A$11.1 million adds to the existing pro forma cas
Slide 25: Indicative Timetable
Indicative Timetable Event Date (2026) For personal use only Trading Halt and bookbuild opens Friday, 3 July 2026 Announcement of Capital Raising and trading halt is lifted Tuesday, 7 July 2026 Settlement of New Shares Issued under the Tranche 1 Placement Friday, 10 July 2026 Allotment of New Shares
Slide 26: Key Risk Factors
Key Risk Factors Specific investment risks meet commercialisation goals. If Imugene is unable to find a partner, it would be required to develop and commercialise potential products at its own expense. • IMU’s products in development and not approved for commercial sale – This may place significant
Slide 27: Key Risk Factors
Key Risk Factors General investment risks Cautionary statement • Investment risks - The price of the Shares might rise or fall and they might trade • Statements in this Presentation may be forward looking statements. Forward at prices below or above the Offer Price. There can also be no assurance th
Slide 28: Foreign Offer Restrictions
Foreign Offer Restrictions This presentation is for information purposes only and is not an invitation or offer 1. is an investment business within the meaning of clause 37 of Schedule 1 of the of securities for subscription, purchase or sale in any jurisdiction. The distribution FMC Act; of this pr
Slide 29: imugene.com
ASX : IMU imugene.com For personal use only Connect with us on LinkedIn @Imugene Limited Watch us on YouTube @ImugeneLimited 29